Leukemia Research
Volume 27, Issue 6 , Pages 529-537 , June 2003

A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH

Received 21 May 2001 ,Accepted 4 October 2002.

References 

  1. Preisler HD. Fitness landscapes and the myeloid leukemia’s. Leuk. Res. 1999;23:167–176
  2. Preisler HD. Evolution of secondary hematologic disorders: preMDS → MDS → sAML. Cancer Treat Res. 2001;108:185–230
  3. Gao XZ, Bi S, Copra H, Devemy E, Venugopal P, Li B, et al.  Cytokine gene activity in AML cells in vivo in patients. Leuk. Res. 1998;22:429–438
  4. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–2333
  5. Mancini M, Cedrone M, Diverio D, Emanuel B, Stul M, Vranckx H, et al.  Use of dual color interphase FISH for the detection of inv (16) in acute myelogenous leukemia at diagnosis. Leukemia. 2000;14:364–368
  6. Dhaene K, Van Marck E, Parwaresch R. Telomeres, telomerase and cancer: an update. Virchows Arch. 2000;437:1–16
  7. Kotelnikov V, Cass L, Coon JS, Spaulding D, Preisler HD. Accuracy of histone H3 messenger RNA in situ hybridization for the assessment of cell proliferation in human tissues. Clin. Cancer Res. 1997;3:669–673
  8. Preisler HD, Raza A, Bonomi P, Taylor S, LaFolette S, Leslie W, et al.  Regrowth resistance as a likely significant contributor to treatment failure in drug-sensitive neoplastic diseases. Cancer Invest. 1997;15:358–369
  9. Ohyashiki K, Ohyashiki JH, Nishimaki J, Toyama K, Ebihara Y, Kato H, et al.  Cytological detection of telomerase activity using an in situ telomeric repeat amplification protocol assay. Cancer Res. 1997;57:2100–2103
  10. Preisler HD, Venugopal P, Gregory SA, Adler S, Gezer S, Hsu WT, et al.  High remission rate in acute myeloblastic leukemia with only two days of chemotherapy. Leuk. Lymphom. 2001;41:333–336
  11. Raza A, Maheshwari Y, Ucar K, Mayers G, Preisler HD. Proliferative characteristics of acute nonlymphocytic leukemia in vivo. Acta Haematol. 1987;77(3):140–145
  12. Dohner H, Stilgenbauer S, Fischer K, Schroder M, Bentz M, Lichter P. Diagnosis and monitoring of chromosome aberration in hematological malignancies by fluorescence in situ hybridization. Stem Cells 1995(Suppl 3):76–82.
  13. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al.  Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011–2015
  14. Li B, Yang J, Andrews C, Chen YX, Toofanfard P, Huang RW, et al.  Telomerase activity in preleukemia and acute myelogenous leukemia. Leuk. Lymphom. 2000;36:579–587
  15. Xu D, Gruber A, Peterson C, Pisa P. Telomerase activity and the expression of telomerase components in acute myelogenous leukemia. Br. J. Hematol. 1998;102:1367–1375
  16. Seol JG, Kim ES, Park WH, Jung CW, Kim BK, Lee YY. Telomerase activity in acute myelogenous leukemia’s: clinical and biological implications. Br. J. Hematol. 1998;100:156–165
  17. Ohyashiki K, Yahata N, Ohyashiki JH, Iwama H, Hayashi S, Ando K, et al.  A combination of semiquantitative telomerase assay and in-cell telomerase activity measurement using exfoliated urothelial cells for the detection of urothelial neoplasia. Cancer. 1998;83:2554–2560
  18. Raza A, Preisler HD, Day R, Yasin Z, White M, Lykins J, et al.  Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics. Blood. 1990;76:2191–2197
  19. Dejmak A, Yahata N, Ohyashiki K, Kakihana M, Takashi H, Kawate N, et al.  Correlation between morphology and telomerase activity in cells from exfoliative lung cytologic specimens. Cancer Cytopathol. 2000;90(2):117–125
  20. Zhang W, Piatyszek MA, Kobayashi T, Estey E, Andreeff M, Deisseroth AB, et al.  Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation inducing agents. Clin. Cancer Res. 1996;2:799–803
  21. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 1995;85(9):2315–2320
  22. Tatematsu K, Nakayama J, Danbara M, Shionoya S, Sato H, Omine M, et al.  Novel quantitative stretch PCR assay that detects a dramatic increase in telomerase activity during the progression of myeloid leukemia’s. Oncogene. 1996;13:2265–2274
  23. Ohyashiki JH, Ohyashiki K, Iwama H, Hayashi S, Toyama K, Shay JW, et al.  Clinical implications of telomerase activity levels in acute leukemia. Clin. Cancer Res. 1997;3:619–625
  24. Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD. Telomerase, cell immortality and cancer. In: Proceedings of the Cold Spring Harbor Symposia on Quantitative Biology, vol. 59; 1994. p. 307–15.
  25. Flint J, Craddock CF, Villegas A, Bentley DP, Williams HJ, Galanello R, et al.  Healing of broken human chromosomes by the addition of telomeric repeats. Am. J. Human Genet. 1994;55:505–512
  26. El-Rifai W, Ruutu T, Elonen E, Volin L, Knuutila S. Prognostic value of metaphase—FISH in follow up of patients with acute myeloid leukemia in remission. Blood. 1997;89(9):3330–3334
  27. Haferlach T, Winkemann M, Nickenig C, Meeder M, Ramm-Petersen L, Schoch R, et al.  Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May–Grunwald–Giemsa staining and fluorescence in situ hybridization techniques. Br. J. Haematol. 1997;97(1):99–106
  28. Preisler HD, Li B, Yang BL, Huang RW, Devemy E, Venugopal P, et al.  Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4. Clin. Cancer Res. 2000;6:807–812

PII: S0145-2126(02)00267-9

doi: 10.1016/S0145-2126(02)00267-9

Leukemia Research
Volume 27, Issue 6 , Pages 529-537 , June 2003

Article Tools

* Image Usage & Resolution